FGF18 and achalasia-alacrima syndrome: The overall incidence rate of AAAs was 0 in the Sham group and 83.3% (40/48) in the experimental (AAA, AAA + FGF18, AAA + LV-Itgβ1, and AAA + FGF18 + LV-Itgβ1) groups.